A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab Pre-treated Patients With HER2-positive Metastatic Breast Cancer (E-VITA).
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Eribulin (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms E-VITA
- 07 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
- 20 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by european Clinical Trials Database.